Oxford Biomedica Solutions
Stephen Boyd has extensive work experience in the biotechnology and pharmaceutical industry. Stephen is currently serving as the Director of Engineering at Oxford Biomedica Solutions since March 2022. Prior to this, they worked at Homology Medicines, Inc. as the Director of Engineering from January 2022 to March 2022 and as the Associate Director of Automation from April 2019 to December 2021. Before Homology Medicines, Inc., Stephen was employed at Shire, where they held the positions of Senior Controls Engineer from December 2010 to March 2019 and Electrical / Controls Engineer from December 2008 to December 2010. Stephen started their career at Wyeth as a Maintenance Engineer II from an unknown month in 2004 to 2008.
Stephen Boyd attended Tufts University from 2014 to 2016, where they obtained a Master's Degree in Engineering Management. Prior to that, they attended Rensselaer Polytechnic Institute from 2000 to 2004, earning a Bachelor of Science (BS) degree in Electrical Engineering.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.